What is the current valuation of the Osteoarthritis Market as of 2024?

The Osteoarthritis Market was valued at 5.12 USD Billion in 2024. Read More

What is the projected market size for the Osteoarthritis Market in 2035?

The market is projected to reach 13.37 USD Billion by 2035. Read More

What is the expected CAGR for the Osteoarthritis Market during the forecast period 2025 - 2035?

The expected CAGR for the Osteoarthritis Market during this period is 9.12%. Read More

Which companies are the key players in the Osteoarthritis Market?

Key players include Pfizer, Johnson & Johnson, Novartis, and AbbVie, among others. Read More

How is the Osteoarthritis Market segmented by type of osteoarthritis?

The market segments include Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Spinal Osteoarthritis. Read More

What were the valuations for Knee Osteoarthritis in 2024 and its projected value in 2035?

Knee Osteoarthritis was valued at 1.54 USD Billion in 2024 and is projected to reach 4.05 USD Billion by 2035. Read More

What are the projected values for pharmacological treatment in the Osteoarthritis Market?

Pharmacological treatment was valued at 1.54 USD Billion in 2024 and is expected to reach 3.92 USD Billion by 2035. Read More

How does the market perform in terms of severity levels of osteoarthritis?

The market segments by severity include Mild, Moderate, and Severe Osteoarthritis, with Moderate Osteoarthritis projected to grow significantly. Read More

What is the market outlook for older adults suffering from osteoarthritis?

The segment for older adults was valued at 3.07 USD Billion in 2024 and is projected to reach 8.98 USD Billion by 2035. Read More

What treatment types are included in the Osteoarthritis Market segmentation?

The market is segmented into Pharmacological Treatment, Non-Pharmacological Treatment, Surgical Treatment, and Rehabilitation. Read More

Osteoarthritis Therapeutics Market

ID: MRFR/Pharma/1078-HCR

90 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Osteoarthritis Market Research Report Information By Type (Hip Osteoarthritis, and Spinal Osteoarthritis), By Diagnosis (Imagining, and Joint Fluid Analysis), By Treatment (Medication, Surgery, Therapy), By End-User (Hospitals, and Medical Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Osteoarthritis Therapeutics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)9.12%

2024 Market Size$ 5.12 Billion

2025 Market Size$ 5.58 Billion

2035 Market Size$ 13.37 Billion

Key Players

Companies such as Pfizer

Johnson & Johnson

Novartis

Bristol-Myers Squibb

AbbVie

Amgen

Trends

Rise of Biologics and Targeted Therapies
Personalized Treatment Approaches
Integration of Digital Health Solutions

Opportunities

Market Growth Projections
Growing Awareness and Education
Increased Healthcare Expenditure

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Osteoarthritis (USD Billion) | |
  1. 4.1.1 Knee Osteoarthritis | |
  2. 4.1.2 Hip Osteoarthritis | |
  3. 4.1.3 Hand Osteoarthritis | |
  4. 4.1.4 Spinal Osteoarthritis |
2. 4.2 Healthcare, BY Treatment Type (USD Billion) | |
  1. 4.2.1 Pharmacological Treatment | |
  2. 4.2.2 Non-Pharmacological Treatment | |
  3. 4.2.3 Surgical Treatment | |
  4. 4.2.4 Rehabilitation |
3. 4.3 Healthcare, BY Severity Level (USD Billion) | |
  1. 4.3.1 Mild Osteoarthritis | |
  2. 4.3.2 Moderate Osteoarthritis | |
  3. 4.3.3 Severe Osteoarthritis |
4. 4.4 Healthcare, BY Age Group (USD Billion) | |
  1. 4.4.1 Young Adults | |
  2. 4.4.2 Middle-Aged Adults | |
  3. 4.4.3 Older Adults |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Johnson & Johnson (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Novartis (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bristol-Myers Squibb (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AbbVie (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Amgen (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sanofi (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GlaxoSmithKline (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Roche (CH) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
7. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE |
8. 6.5 US MARKET ANALYSIS BY SEVERITY LEVEL |
9. 6.6 US MARKET ANALYSIS BY AGE GROUP |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
11. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY SEVERITY LEVEL |
13. 6.10 CANADA MARKET ANALYSIS BY AGE GROUP |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
16. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY SEVERITY LEVEL |
18. 6.15 GERMANY MARKET ANALYSIS BY AGE GROUP |
19. 6.16 UK MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
20. 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE |
21. 6.18 UK MARKET ANALYSIS BY SEVERITY LEVEL |
22. 6.19 UK MARKET ANALYSIS BY AGE GROUP |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
24. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY SEVERITY LEVEL |
26. 6.23 FRANCE MARKET ANALYSIS BY AGE GROUP |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
28. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY SEVERITY LEVEL |
30. 6.27 RUSSIA MARKET ANALYSIS BY AGE GROUP |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
32. 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY SEVERITY LEVEL |
34. 6.31 ITALY MARKET ANALYSIS BY AGE GROUP |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
36. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY SEVERITY LEVEL |
38. 6.35 SPAIN MARKET ANALYSIS BY AGE GROUP |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY SEVERITY LEVEL |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
45. 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY SEVERITY LEVEL |
47. 6.44 CHINA MARKET ANALYSIS BY AGE GROUP |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
49. 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY SEVERITY LEVEL |
51. 6.48 INDIA MARKET ANALYSIS BY AGE GROUP |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
53. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY SEVERITY LEVEL |
55. 6.52 JAPAN MARKET ANALYSIS BY AGE GROUP |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY SEVERITY LEVEL |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
61. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY SEVERITY LEVEL |
63. 6.60 MALAYSIA MARKET ANALYSIS BY AGE GROUP |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
65. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY SEVERITY LEVEL |
67. 6.64 THAILAND MARKET ANALYSIS BY AGE GROUP |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
69. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY SEVERITY LEVEL |
71. 6.68 INDONESIA MARKET ANALYSIS BY AGE GROUP |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
73. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY SEVERITY LEVEL |
75. 6.72 REST OF APAC MARKET ANALYSIS BY AGE GROUP |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
78. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY SEVERITY LEVEL |
80. 6.77 BRAZIL MARKET ANALYSIS BY AGE GROUP |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
82. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY SEVERITY LEVEL |
84. 6.81 MEXICO MARKET ANALYSIS BY AGE GROUP |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
86. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY SEVERITY LEVEL |
88. 6.85 ARGENTINA MARKET ANALYSIS BY AGE GROUP |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY LEVEL |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY LEVEL |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY LEVEL |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS |
103. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY SEVERITY LEVEL |
105. 6.102 REST OF MEA MARKET ANALYSIS BY AGE GROUP |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE OF OSTEOARTHRITIS, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE OF OSTEOARTHRITIS, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY SEVERITY LEVEL, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY SEVERITY LEVEL, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY AGE GROUP, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY AGE GROUP, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY AGE GROUP, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY AGE GROUP, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY AGE GROUP, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY AGE GROUP, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY AGE GROUP, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY AGE GROUP, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY AGE GROUP, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY AGE GROUP, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY AGE GROUP, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY AGE GROUP, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY AGE GROUP, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY AGE GROUP, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY AGE GROUP, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY AGE GROUP, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY AGE GROUP, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY AGE GROUP, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY AGE GROUP, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY AGE GROUP, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY AGE GROUP, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY AGE GROUP, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY AGE GROUP, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY AGE GROUP, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY AGE GROUP, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY AGE GROUP, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY AGE GROUP, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY AGE GROUP, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Osteoarthritis Market Segmentation

Osteoarthritis Market By Type of Osteoarthritis (USD Billion, 2025-2035)

Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Spinal Osteoarthritis

Osteoarthritis Market By Treatment Type (USD Billion, 2025-2035)

Pharmacological Treatment
Non-Pharmacological Treatment
Surgical Treatment
Rehabilitation

Osteoarthritis Market By Severity Level (USD Billion, 2025-2035)

Mild Osteoarthritis
Moderate Osteoarthritis
Severe Osteoarthritis

Osteoarthritis Market By Age Group (USD Billion, 2025-2035)

Young Adults
Middle-Aged Adults
Older Adults

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”